Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.60 |
| ▸ | TACR1 | P25103 | 10/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 6/20 | 0.59 |
| ▸ | IL1RN | P18510 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12966271 | 0.94 | MAPT (0.66) | TACR1MAPTLMNATP53THRB | |
| SCHEMBL9931193 | 0.94 | MAPT (0.66) | TACR1MAPTLMNATP53THRB | |
| SCHEMBL9931444 | 0.94 | MAPT (0.66) | TACR1MAPTLMNATP53THRB | |
| SCHEMBL9966740 | 0.93 | MEN1 (0.65) | LNPEPTACR1ERAP2ERAP1IL1RN | |
| SCHEMBL15591438 | 0.93 | MEN1 (0.65) | LNPEPTACR1ERAP2ERAP1IL1RN | |
| Hydrochloric Acid SCHEMBL12819455 | 0.93 | MAPT (0.65) | TACR1MAPTLMNATP53THRB | |
| Hydrochloric Acid SCHEMBL645269 | 0.92 | MEN1 (0.64) | LNPEPTACR1ERAP2ERAP1IL1RN | |
| SCHEMBL9931405 | 0.91 | LNPEP (0.67) | LNPEPTACR1ERAP2ERAP1IL1RN | |
| SCHEMBL16250712 | 0.91 | LNPEP (0.61) | LNPEPTACR1ERAP2ERAP1IL1RN | |
| SCHEMBL12966277 | 0.91 | ERAP2 (0.60) | LNPEPTACR1ERAP2ERAP1IL1RN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013123574-A1 | ORALLY BIOAVAILABLE DERIVATIVES OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-29 | — | — | WO | disclosed |
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | TPH1, TPH2, GLUL | LNPEP 131/4885TACR1 1700/4885ERAP2 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.